### Highlights of This Issue 1621

#### SPECIAL FEATURES

**CCR Drug Updates**

1623  Nivolumab in the Treatment of Hodgkin Lymphoma  
Stephen M. Ansell

**CCR Focus**

1628  Pancreatic Cancer: Challenge and Inspiration  
Susan E. Bates

1629  Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma"  
Erkut Borazanci, Chi V. Dang, Robert W. Robey, Susan E. Bates, John A. Chabot, and Daniel D. Von Hoff

1638  Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development  
Stephan B. Dreyer, David K. Chang, Peter Bailey, and Andrew V. Biankin

1647  Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program"  
Gerard I. Evan, Nasun Hah, Trevor D. Littlewood, Nicole M. Sodir, Tania Campos, Michael Downes, and Ronald M. Evans

**CANCER THERAPY: CLINICAL**

1679  Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study  
Annemieke J.M. Nieuweboer, Anne-Joy M. de Graan, Paul Hamberg, Sander Bins, Robert J. van Soest, Robbert J. van Alphen, Andries M. Bergman, Aart Beeker, Henk van Halteren, Albert J. ten Tije, Hanneke Zuutienhorst, Nelly van der Meer, Dana Chitu, Ronald de Wit, and Ron H.J. Mathijsen, on behalf of the Dutch Uro-Oncology Studygroup (DUOS)

1684  Oral Bisphosphonates and Improved Survival of Breast Cancer  
Gad Rennert, Mila Pinchev, Naomi Gronich, Walid Saliba, Anath Flugelman, Idit Lavi, Hadassah Goldberg, Georgeta Fried, Mariana Steiner, Arie Binnerman, Keren Landsman, and Hedy S. Rennert

1690  Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment  
Ming-Lung Yu, Chung-Feng Huang, Ming-Lun Yeh, Pei-Chien Tsai, Ching-I. Huang, Meng-Hsuan Hsieh, Ming-Yen Hsieh, Ziu-Yau Lin, Shinn-Cheng Chen, Jee-Fu Huang, Chia-Yen Dai, and Wan-Lung Chuang

**PERSONALIZED MEDICINE AND IMAGING**

1698  Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host  
James H. Park, Hester van Wyk, Donald C. McMillan, Jean Quinn, Jennifer Clark, Campbell S.D. Roxburgh, Paul G. Horgan, and Joanne Edwards

1710  Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen  
Heather M. Brechbuhl, Jessica Finlay-Schultz, Tomomi M. Yamamoto, Austin E. Gillen, Diana M. Cittelly, Aik-Choon Tan, Sharon B. Sams, Manoj M. Pillai, Anthony D. Elias, William A. Robinson, Carol A. Sartorius, and Peter Kabos
1722 Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters
Anders Carlsson, Peter Kuhn, Madelyn S. Luttgen, Kevin K. Dixon, Patricia Troncoso, Paul G. Conn, Anand Kolaskar, James B. Hicks, Christopher J. Logothetis, and Amado J. Zurita

1733 The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway
Katia Beider, Evgenia Rosenberg, Hanna Bitner, Avichai Shimoni, Merav Leiba, Maya Koren-Michowitz, Elena Ribakovskvy, Shiri Klein, Devorah Olami, Lola Weiss, Hanna Wald, Michal Abraham, Elilhan Galun, Amnon Peled, and Amnon Nagler

1748 Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma

1759 Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring

1771 Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivty
Seiichi Odate, Veronica Veschi, Shuang Yan, Norris Lam, Richard Woessner, and Carol J. Thiele

1785 Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma
Lori S. Hart, JulieAnn Rader, Pichai Raman, Vandana Batra, Mike R. Russel, Matthew Tsang, Maria Gagliardi, Lucy Chen, Daniel Martinez, Yimei Li, Andrew Wood, Sunkyu Kim, Sudha Parashuraman, Scott Delach, Kristina A. Cole, Shiva Krupu, Markus Boehm, Malte Peters, Giordano Caponigro, and John M. Maris

1797 Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression
Heather Nesbit, Niall M. Byrne, S. Nicole Williams, Louise Ming, Jenny Worthington, Rachel J. Errington, Laurence H. Patterson, Paul J. Smith, Stephanie R. McKeown, and Declan J. McKenna

1809 BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection—Implications for Oncolytic Viral Therapy
Chelsea Bolyard, W. Hans Meisen, Yeshavantar Banasavadi-Siddigowda, Jayson Hardcastle, Ji Young Yoo, Eric S. Wohleb, Jeffrey Wojcick, Jun-Gy Yu, Samuel Dubin, Maninder Khosla, Bo Xu, Jonathan Smith, Christopher Alvarez-Breckenridge, Peter Pow-anpongkol, Flavia Pichiorri, Jianying Zhang, Matthew Old, Dan Zhu, Erwin G. Van Meir, Jonathan P. Godbout, Michael A. Caligiuri, Jianhua Yu, and Balveen Kaur

1820 The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma
Colin Keane, Clare Good, Kimberly Jones, David Hamm, Dipali Taladilkar, Jonathan Ellis, Frank-Vari, Simone Birch, Erica Han, Peter Wood, Kim-Anh Le-Cao, Michael R. Green, Pauline Crooks, Sanjiv Jain, Josh Tobin, Raymond J. Steptoe, and Maher K. Gandhi

1829 Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer
Johannes Brägelmann, Niklas Klüper, Anne Offermann, Anne von Mässenhausen, Diana Böhmer, Mario Deng, Angela Queisser, Christine Sanders, Isabella Syring, Axel S. Messeburger, Wenzel Vogel, Elisabeth Sievers, Ignacija Vlastic, Jessica Carlsson, Ove Andrén, Peter Brossart, Stefan Dueningsen, Maria A. Svensson, Zahi Shaikhbrahim, Jutta Kiefel, and Sven Perner

1841 Landscape of Genomic Alterations in Pituitary Adenomas
1852  Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors

1862  Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition

CORRECTION
1875  Correction: ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy

ABOUT THE COVER
Estrogen receptor expression and response to antiendocrine therapy in luminal breast cancer are dependent on fibroblast subtypes present in the tumor microenvironment. The cover shows strong estrogen receptor alpha staining (red) in luminal breast cancer cells (green) supported by the presence of CD146pos fibroblasts. For details, see the article by Brechbuhl and colleagues on page 1710 of this issue.